ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2026
Reply to: In DeFi-ance of "More Is Better": Questioning Long-Term Nirogacestat Use in Desmoid Tumors.
Abstract read
In one paragraph
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Ravin Ratanavin Ratan, MD, MEd, Division of Cancer Medicine, Department of Sarcoma Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, TX; Bernd Kasper, MD, PhD, Sarcoma Unit, Mannheim University Medical Center, Mannheim Cancer Center, University of Heidelberg, Mannheim, Germany; Thierry Alcindor, MD, MS, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA; Patrick Schöffski, MD, Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, KU Leuven, Leuven, Belgium; Winette T. van der Graaf, MD, PhD, Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Noah Federman, MD, Departments of Pediatrics and Orthopedics, UCLA Jonsson Comprehensive Cancer Center, UCLA David Geffen School of Medicine, Los Angeles, CA; Nam Q. Bui, MD, Division of Oncology, Department of Medicine, Stanford University, Stanford, CA; Gina D'Amato, MD, Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL; Richard F. Riedel, MD, Duke Cancer Institute, Duke University Medical Center, Durham, NC; Steven Attia, DO, Department of Hematology and Oncology, Mayo Clinic, Jacksonville, FL; Sant Chawla, MD, Sarcoma Oncology Center, Santa Monica, CA; Allison Lim, PharmD, Brad Tumminello, PharmD, and Ana B. Oton, MD, SpringWorks Therapeutics, Inc, a healthcare company of Merck KGaA, Darmstadt, Germany; Yucheng Chu, MS, Sumptuous Data Sciences, Monmouth Junction, NJ; Shengfan Zhou, MS, SpringWorks Therapeutics, Inc, a healthcare company of Merck KGaA, Darmstadt, Germany; and Mrinal Gounder, MD, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY.ORCID 0000-0002-4914-7922
Bernd Kasperavin Ratan, MD, MEd, Division of Cancer Medicine, Department of Sarcoma Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, TX; Bernd Kasper, MD, PhD, Sarcoma Unit, Mannheim University Medical Center, Mannheim Cancer Center, University of Heidelberg, Mannheim, Germany; Thierry Alcindor, MD, MS, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA; Patrick Schöffski, MD, Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, KU Leuven, Leuven, Belgium; Winette T. van der Graaf, MD, PhD, Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Noah Federman, MD, Departments of Pediatrics and Orthopedics, UCLA Jonsson Comprehensive Cancer Center, UCLA David Geffen School of Medicine, Los Angeles, CA; Nam Q. Bui, MD, Division of Oncology, Department of Medicine, Stanford University, Stanford, CA; Gina D'Amato, MD, Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL; Richard F. Riedel, MD, Duke Cancer Institute, Duke University Medical Center, Durham, NC; Steven Attia, DO, Department of Hematology and Oncology, Mayo Clinic, Jacksonville, FL; Sant Chawla, MD, Sarcoma Oncology Center, Santa Monica, CA; Allison Lim, PharmD, Brad Tumminello, PharmD, and Ana B. Oton, MD, SpringWorks Therapeutics, Inc, a healthcare company of Merck KGaA, Darmstadt, Germany; Yucheng Chu, MS, Sumptuous Data Sciences, Monmouth Junction, NJ; Shengfan Zhou, MS, SpringWorks Therapeutics, Inc, a healthcare company of Merck KGaA, Darmstadt, Germany; and Mrinal Gounder, MD, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY.ORCID 0000-0001-8425-8356
Thierry Alcindoravin Ratan, MD, MEd, Division of Cancer Medicine, Department of Sarcoma Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, TX; Bernd Kasper, MD, PhD, Sarcoma Unit, Mannheim University Medical Center, Mannheim Cancer Center, University of Heidelberg, Mannheim, Germany; Thierry Alcindor, MD, MS, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA; Patrick Schöffski, MD, Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, KU Leuven, Leuven, Belgium; Winette T. van der Graaf, MD, PhD, Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Noah Federman, MD, Departments of Pediatrics and Orthopedics, UCLA Jonsson Comprehensive Cancer Center, UCLA David Geffen School of Medicine, Los Angeles, CA; Nam Q. Bui, MD, Division of Oncology, Department of Medicine, Stanford University, Stanford, CA; Gina D'Amato, MD, Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL; Richard F. Riedel, MD, Duke Cancer Institute, Duke University Medical Center, Durham, NC; Steven Attia, DO, Department of Hematology and Oncology, Mayo Clinic, Jacksonville, FL; Sant Chawla, MD, Sarcoma Oncology Center, Santa Monica, CA; Allison Lim, PharmD, Brad Tumminello, PharmD, and Ana B. Oton, MD, SpringWorks Therapeutics, Inc, a healthcare company of Merck KGaA, Darmstadt, Germany; Yucheng Chu, MS, Sumptuous Data Sciences, Monmouth Junction, NJ; Shengfan Zhou, MS, SpringWorks Therapeutics, Inc, a healthcare company of Merck KGaA, Darmstadt, Germany; and Mrinal Gounder, MD, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY.ORCID 0000-0002-6004-0405
Patrick Schöffskiavin Ratan, MD, MEd, Division of Cancer Medicine, Department of Sarcoma Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, TX; Bernd Kasper, MD, PhD, Sarcoma Unit, Mannheim University Medical Center, Mannheim Cancer Center, University of Heidelberg, Mannheim, Germany; Thierry Alcindor, MD, MS, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA; Patrick Schöffski, MD, Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, KU Leuven, Leuven, Belgium; Winette T. van der Graaf, MD, PhD, Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Noah Federman, MD, Departments of Pediatrics and Orthopedics, UCLA Jonsson Comprehensive Cancer Center, UCLA David Geffen School of Medicine, Los Angeles, CA; Nam Q. Bui, MD, Division of Oncology, Department of Medicine, Stanford University, Stanford, CA; Gina D'Amato, MD, Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL; Richard F. Riedel, MD, Duke Cancer Institute, Duke University Medical Center, Durham, NC; Steven Attia, DO, Department of Hematology and Oncology, Mayo Clinic, Jacksonville, FL; Sant Chawla, MD, Sarcoma Oncology Center, Santa Monica, CA; Allison Lim, PharmD, Brad Tumminello, PharmD, and Ana B. Oton, MD, SpringWorks Therapeutics, Inc, a healthcare company of Merck KGaA, Darmstadt, Germany; Yucheng Chu, MS, Sumptuous Data Sciences, Monmouth Junction, NJ; Shengfan Zhou, MS, SpringWorks Therapeutics, Inc, a healthcare company of Merck KGaA, Darmstadt, Germany; and Mrinal Gounder, MD, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY.ORCID 0000-0001-5980-030X
Winette T van der Graafavin Ratan, MD, MEd, Division of Cancer Medicine, Department of Sarcoma Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, TX; Bernd Kasper, MD, PhD, Sarcoma Unit, Mannheim University Medical Center, Mannheim Cancer Center, University of Heidelberg, Mannheim, Germany; Thierry Alcindor, MD, MS, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA; Patrick Schöffski, MD, Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, KU Leuven, Leuven, Belgium; Winette T. van der Graaf, MD, PhD, Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Noah Federman, MD, Departments of Pediatrics and Orthopedics, UCLA Jonsson Comprehensive Cancer Center, UCLA David Geffen School of Medicine, Los Angeles, CA; Nam Q. Bui, MD, Division of Oncology, Department of Medicine, Stanford University, Stanford, CA; Gina D'Amato, MD, Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL; Richard F. Riedel, MD, Duke Cancer Institute, Duke University Medical Center, Durham, NC; Steven Attia, DO, Department of Hematology and Oncology, Mayo Clinic, Jacksonville, FL; Sant Chawla, MD, Sarcoma Oncology Center, Santa Monica, CA; Allison Lim, PharmD, Brad Tumminello, PharmD, and Ana B. Oton, MD, SpringWorks Therapeutics, Inc, a healthcare company of Merck KGaA, Darmstadt, Germany; Yucheng Chu, MS, Sumptuous Data Sciences, Monmouth Junction, NJ; Shengfan Zhou, MS, SpringWorks Therapeutics, Inc, a healthcare company of Merck KGaA, Darmstadt, Germany; and Mrinal Gounder, MD, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY.ORCID 0000-0001-7549-3338
Noah Federmanavin Ratan, MD, MEd, Division of Cancer Medicine, Department of Sarcoma Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, TX; Bernd Kasper, MD, PhD, Sarcoma Unit, Mannheim University Medical Center, Mannheim Cancer Center, University of Heidelberg, Mannheim, Germany; Thierry Alcindor, MD, MS, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA; Patrick Schöffski, MD, Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, KU Leuven, Leuven, Belgium; Winette T. van der Graaf, MD, PhD, Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Noah Federman, MD, Departments of Pediatrics and Orthopedics, UCLA Jonsson Comprehensive Cancer Center, UCLA David Geffen School of Medicine, Los Angeles, CA; Nam Q. Bui, MD, Division of Oncology, Department of Medicine, Stanford University, Stanford, CA; Gina D'Amato, MD, Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL; Richard F. Riedel, MD, Duke Cancer Institute, Duke University Medical Center, Durham, NC; Steven Attia, DO, Department of Hematology and Oncology, Mayo Clinic, Jacksonville, FL; Sant Chawla, MD, Sarcoma Oncology Center, Santa Monica, CA; Allison Lim, PharmD, Brad Tumminello, PharmD, and Ana B. Oton, MD, SpringWorks Therapeutics, Inc, a healthcare company of Merck KGaA, Darmstadt, Germany; Yucheng Chu, MS, Sumptuous Data Sciences, Monmouth Junction, NJ; Shengfan Zhou, MS, SpringWorks Therapeutics, Inc, a healthcare company of Merck KGaA, Darmstadt, Germany; and Mrinal Gounder, MD, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY.
Nam Q Buiavin Ratan, MD, MEd, Division of Cancer Medicine, Department of Sarcoma Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, TX; Bernd Kasper, MD, PhD, Sarcoma Unit, Mannheim University Medical Center, Mannheim Cancer Center, University of Heidelberg, Mannheim, Germany; Thierry Alcindor, MD, MS, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA; Patrick Schöffski, MD, Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, KU Leuven, Leuven, Belgium; Winette T. van der Graaf, MD, PhD, Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Noah Federman, MD, Departments of Pediatrics and Orthopedics, UCLA Jonsson Comprehensive Cancer Center, UCLA David Geffen School of Medicine, Los Angeles, CA; Nam Q. Bui, MD, Division of Oncology, Department of Medicine, Stanford University, Stanford, CA; Gina D'Amato, MD, Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL; Richard F. Riedel, MD, Duke Cancer Institute, Duke University Medical Center, Durham, NC; Steven Attia, DO, Department of Hematology and Oncology, Mayo Clinic, Jacksonville, FL; Sant Chawla, MD, Sarcoma Oncology Center, Santa Monica, CA; Allison Lim, PharmD, Brad Tumminello, PharmD, and Ana B. Oton, MD, SpringWorks Therapeutics, Inc, a healthcare company of Merck KGaA, Darmstadt, Germany; Yucheng Chu, MS, Sumptuous Data Sciences, Monmouth Junction, NJ; Shengfan Zhou, MS, SpringWorks Therapeutics, Inc, a healthcare company of Merck KGaA, Darmstadt, Germany; and Mrinal Gounder, MD, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY.ORCID 0000-0001-6896-4349
Gina D'Amatoavin Ratan, MD, MEd, Division of Cancer Medicine, Department of Sarcoma Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, TX; Bernd Kasper, MD, PhD, Sarcoma Unit, Mannheim University Medical Center, Mannheim Cancer Center, University of Heidelberg, Mannheim, Germany; Thierry Alcindor, MD, MS, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA; Patrick Schöffski, MD, Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, KU Leuven, Leuven, Belgium; Winette T. van der Graaf, MD, PhD, Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Noah Federman, MD, Departments of Pediatrics and Orthopedics, UCLA Jonsson Comprehensive Cancer Center, UCLA David Geffen School of Medicine, Los Angeles, CA; Nam Q. Bui, MD, Division of Oncology, Department of Medicine, Stanford University, Stanford, CA; Gina D'Amato, MD, Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL; Richard F. Riedel, MD, Duke Cancer Institute, Duke University Medical Center, Durham, NC; Steven Attia, DO, Department of Hematology and Oncology, Mayo Clinic, Jacksonville, FL; Sant Chawla, MD, Sarcoma Oncology Center, Santa Monica, CA; Allison Lim, PharmD, Brad Tumminello, PharmD, and Ana B. Oton, MD, SpringWorks Therapeutics, Inc, a healthcare company of Merck KGaA, Darmstadt, Germany; Yucheng Chu, MS, Sumptuous Data Sciences, Monmouth Junction, NJ; Shengfan Zhou, MS, SpringWorks Therapeutics, Inc, a healthcare company of Merck KGaA, Darmstadt, Germany; and Mrinal Gounder, MD, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY.
Richard F Riedelavin Ratan, MD, MEd, Division of Cancer Medicine, Department of Sarcoma Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, TX; Bernd Kasper, MD, PhD, Sarcoma Unit, Mannheim University Medical Center, Mannheim Cancer Center, University of Heidelberg, Mannheim, Germany; Thierry Alcindor, MD, MS, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA; Patrick Schöffski, MD, Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, KU Leuven, Leuven, Belgium; Winette T. van der Graaf, MD, PhD, Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Noah Federman, MD, Departments of Pediatrics and Orthopedics, UCLA Jonsson Comprehensive Cancer Center, UCLA David Geffen School of Medicine, Los Angeles, CA; Nam Q. Bui, MD, Division of Oncology, Department of Medicine, Stanford University, Stanford, CA; Gina D'Amato, MD, Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL; Richard F. Riedel, MD, Duke Cancer Institute, Duke University Medical Center, Durham, NC; Steven Attia, DO, Department of Hematology and Oncology, Mayo Clinic, Jacksonville, FL; Sant Chawla, MD, Sarcoma Oncology Center, Santa Monica, CA; Allison Lim, PharmD, Brad Tumminello, PharmD, and Ana B. Oton, MD, SpringWorks Therapeutics, Inc, a healthcare company of Merck KGaA, Darmstadt, Germany; Yucheng Chu, MS, Sumptuous Data Sciences, Monmouth Junction, NJ; Shengfan Zhou, MS, SpringWorks Therapeutics, Inc, a healthcare company of Merck KGaA, Darmstadt, Germany; and Mrinal Gounder, MD, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY.ORCID 0000-0001-5412-8710
Steven Attiaavin Ratan, MD, MEd, Division of Cancer Medicine, Department of Sarcoma Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, TX; Bernd Kasper, MD, PhD, Sarcoma Unit, Mannheim University Medical Center, Mannheim Cancer Center, University of Heidelberg, Mannheim, Germany; Thierry Alcindor, MD, MS, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA; Patrick Schöffski, MD, Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, KU Leuven, Leuven, Belgium; Winette T. van der Graaf, MD, PhD, Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Noah Federman, MD, Departments of Pediatrics and Orthopedics, UCLA Jonsson Comprehensive Cancer Center, UCLA David Geffen School of Medicine, Los Angeles, CA; Nam Q. Bui, MD, Division of Oncology, Department of Medicine, Stanford University, Stanford, CA; Gina D'Amato, MD, Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL; Richard F. Riedel, MD, Duke Cancer Institute, Duke University Medical Center, Durham, NC; Steven Attia, DO, Department of Hematology and Oncology, Mayo Clinic, Jacksonville, FL; Sant Chawla, MD, Sarcoma Oncology Center, Santa Monica, CA; Allison Lim, PharmD, Brad Tumminello, PharmD, and Ana B. Oton, MD, SpringWorks Therapeutics, Inc, a healthcare company of Merck KGaA, Darmstadt, Germany; Yucheng Chu, MS, Sumptuous Data Sciences, Monmouth Junction, NJ; Shengfan Zhou, MS, SpringWorks Therapeutics, Inc, a healthcare company of Merck KGaA, Darmstadt, Germany; and Mrinal Gounder, MD, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY.ORCID 0000-0003-1745-4773
Sant Chawlaavin Ratan, MD, MEd, Division of Cancer Medicine, Department of Sarcoma Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, TX; Bernd Kasper, MD, PhD, Sarcoma Unit, Mannheim University Medical Center, Mannheim Cancer Center, University of Heidelberg, Mannheim, Germany; Thierry Alcindor, MD, MS, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA; Patrick Schöffski, MD, Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, KU Leuven, Leuven, Belgium; Winette T. van der Graaf, MD, PhD, Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Noah Federman, MD, Departments of Pediatrics and Orthopedics, UCLA Jonsson Comprehensive Cancer Center, UCLA David Geffen School of Medicine, Los Angeles, CA; Nam Q. Bui, MD, Division of Oncology, Department of Medicine, Stanford University, Stanford, CA; Gina D'Amato, MD, Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL; Richard F. Riedel, MD, Duke Cancer Institute, Duke University Medical Center, Durham, NC; Steven Attia, DO, Department of Hematology and Oncology, Mayo Clinic, Jacksonville, FL; Sant Chawla, MD, Sarcoma Oncology Center, Santa Monica, CA; Allison Lim, PharmD, Brad Tumminello, PharmD, and Ana B. Oton, MD, SpringWorks Therapeutics, Inc, a healthcare company of Merck KGaA, Darmstadt, Germany; Yucheng Chu, MS, Sumptuous Data Sciences, Monmouth Junction, NJ; Shengfan Zhou, MS, SpringWorks Therapeutics, Inc, a healthcare company of Merck KGaA, Darmstadt, Germany; and Mrinal Gounder, MD, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY.
Allison Limavin Ratan, MD, MEd, Division of Cancer Medicine, Department of Sarcoma Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, TX; Bernd Kasper, MD, PhD, Sarcoma Unit, Mannheim University Medical Center, Mannheim Cancer Center, University of Heidelberg, Mannheim, Germany; Thierry Alcindor, MD, MS, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA; Patrick Schöffski, MD, Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, KU Leuven, Leuven, Belgium; Winette T. van der Graaf, MD, PhD, Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Noah Federman, MD, Departments of Pediatrics and Orthopedics, UCLA Jonsson Comprehensive Cancer Center, UCLA David Geffen School of Medicine, Los Angeles, CA; Nam Q. Bui, MD, Division of Oncology, Department of Medicine, Stanford University, Stanford, CA; Gina D'Amato, MD, Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL; Richard F. Riedel, MD, Duke Cancer Institute, Duke University Medical Center, Durham, NC; Steven Attia, DO, Department of Hematology and Oncology, Mayo Clinic, Jacksonville, FL; Sant Chawla, MD, Sarcoma Oncology Center, Santa Monica, CA; Allison Lim, PharmD, Brad Tumminello, PharmD, and Ana B. Oton, MD, SpringWorks Therapeutics, Inc, a healthcare company of Merck KGaA, Darmstadt, Germany; Yucheng Chu, MS, Sumptuous Data Sciences, Monmouth Junction, NJ; Shengfan Zhou, MS, SpringWorks Therapeutics, Inc, a healthcare company of Merck KGaA, Darmstadt, Germany; and Mrinal Gounder, MD, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY.ORCID 0000-0001-9187-8465
Brad Tumminelloavin Ratan, MD, MEd, Division of Cancer Medicine, Department of Sarcoma Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, TX; Bernd Kasper, MD, PhD, Sarcoma Unit, Mannheim University Medical Center, Mannheim Cancer Center, University of Heidelberg, Mannheim, Germany; Thierry Alcindor, MD, MS, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA; Patrick Schöffski, MD, Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, KU Leuven, Leuven, Belgium; Winette T. van der Graaf, MD, PhD, Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Noah Federman, MD, Departments of Pediatrics and Orthopedics, UCLA Jonsson Comprehensive Cancer Center, UCLA David Geffen School of Medicine, Los Angeles, CA; Nam Q. Bui, MD, Division of Oncology, Department of Medicine, Stanford University, Stanford, CA; Gina D'Amato, MD, Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL; Richard F. Riedel, MD, Duke Cancer Institute, Duke University Medical Center, Durham, NC; Steven Attia, DO, Department of Hematology and Oncology, Mayo Clinic, Jacksonville, FL; Sant Chawla, MD, Sarcoma Oncology Center, Santa Monica, CA; Allison Lim, PharmD, Brad Tumminello, PharmD, and Ana B. Oton, MD, SpringWorks Therapeutics, Inc, a healthcare company of Merck KGaA, Darmstadt, Germany; Yucheng Chu, MS, Sumptuous Data Sciences, Monmouth Junction, NJ; Shengfan Zhou, MS, SpringWorks Therapeutics, Inc, a healthcare company of Merck KGaA, Darmstadt, Germany; and Mrinal Gounder, MD, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY.ORCID 0009-0004-0967-7330
Ana B Otonavin Ratan, MD, MEd, Division of Cancer Medicine, Department of Sarcoma Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, TX; Bernd Kasper, MD, PhD, Sarcoma Unit, Mannheim University Medical Center, Mannheim Cancer Center, University of Heidelberg, Mannheim, Germany; Thierry Alcindor, MD, MS, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA; Patrick Schöffski, MD, Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, KU Leuven, Leuven, Belgium; Winette T. van der Graaf, MD, PhD, Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Noah Federman, MD, Departments of Pediatrics and Orthopedics, UCLA Jonsson Comprehensive Cancer Center, UCLA David Geffen School of Medicine, Los Angeles, CA; Nam Q. Bui, MD, Division of Oncology, Department of Medicine, Stanford University, Stanford, CA; Gina D'Amato, MD, Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL; Richard F. Riedel, MD, Duke Cancer Institute, Duke University Medical Center, Durham, NC; Steven Attia, DO, Department of Hematology and Oncology, Mayo Clinic, Jacksonville, FL; Sant Chawla, MD, Sarcoma Oncology Center, Santa Monica, CA; Allison Lim, PharmD, Brad Tumminello, PharmD, and Ana B. Oton, MD, SpringWorks Therapeutics, Inc, a healthcare company of Merck KGaA, Darmstadt, Germany; Yucheng Chu, MS, Sumptuous Data Sciences, Monmouth Junction, NJ; Shengfan Zhou, MS, SpringWorks Therapeutics, Inc, a healthcare company of Merck KGaA, Darmstadt, Germany; and Mrinal Gounder, MD, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY.
Yucheng Chuavin Ratan, MD, MEd, Division of Cancer Medicine, Department of Sarcoma Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, TX; Bernd Kasper, MD, PhD, Sarcoma Unit, Mannheim University Medical Center, Mannheim Cancer Center, University of Heidelberg, Mannheim, Germany; Thierry Alcindor, MD, MS, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA; Patrick Schöffski, MD, Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, KU Leuven, Leuven, Belgium; Winette T. van der Graaf, MD, PhD, Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Noah Federman, MD, Departments of Pediatrics and Orthopedics, UCLA Jonsson Comprehensive Cancer Center, UCLA David Geffen School of Medicine, Los Angeles, CA; Nam Q. Bui, MD, Division of Oncology, Department of Medicine, Stanford University, Stanford, CA; Gina D'Amato, MD, Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL; Richard F. Riedel, MD, Duke Cancer Institute, Duke University Medical Center, Durham, NC; Steven Attia, DO, Department of Hematology and Oncology, Mayo Clinic, Jacksonville, FL; Sant Chawla, MD, Sarcoma Oncology Center, Santa Monica, CA; Allison Lim, PharmD, Brad Tumminello, PharmD, and Ana B. Oton, MD, SpringWorks Therapeutics, Inc, a healthcare company of Merck KGaA, Darmstadt, Germany; Yucheng Chu, MS, Sumptuous Data Sciences, Monmouth Junction, NJ; Shengfan Zhou, MS, SpringWorks Therapeutics, Inc, a healthcare company of Merck KGaA, Darmstadt, Germany; and Mrinal Gounder, MD, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY.
Shengfan Zhouavin Ratan, MD, MEd, Division of Cancer Medicine, Department of Sarcoma Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, TX; Bernd Kasper, MD, PhD, Sarcoma Unit, Mannheim University Medical Center, Mannheim Cancer Center, University of Heidelberg, Mannheim, Germany; Thierry Alcindor, MD, MS, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA; Patrick Schöffski, MD, Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, KU Leuven, Leuven, Belgium; Winette T. van der Graaf, MD, PhD, Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Noah Federman, MD, Departments of Pediatrics and Orthopedics, UCLA Jonsson Comprehensive Cancer Center, UCLA David Geffen School of Medicine, Los Angeles, CA; Nam Q. Bui, MD, Division of Oncology, Department of Medicine, Stanford University, Stanford, CA; Gina D'Amato, MD, Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL; Richard F. Riedel, MD, Duke Cancer Institute, Duke University Medical Center, Durham, NC; Steven Attia, DO, Department of Hematology and Oncology, Mayo Clinic, Jacksonville, FL; Sant Chawla, MD, Sarcoma Oncology Center, Santa Monica, CA; Allison Lim, PharmD, Brad Tumminello, PharmD, and Ana B. Oton, MD, SpringWorks Therapeutics, Inc, a healthcare company of Merck KGaA, Darmstadt, Germany; Yucheng Chu, MS, Sumptuous Data Sciences, Monmouth Junction, NJ; Shengfan Zhou, MS, SpringWorks Therapeutics, Inc, a healthcare company of Merck KGaA, Darmstadt, Germany; and Mrinal Gounder, MD, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY.
Mrinal Gounderavin Ratan, MD, MEd, Division of Cancer Medicine, Department of Sarcoma Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, TX; Bernd Kasper, MD, PhD, Sarcoma Unit, Mannheim University Medical Center, Mannheim Cancer Center, University of Heidelberg, Mannheim, Germany; Thierry Alcindor, MD, MS, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA; Patrick Schöffski, MD, Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, KU Leuven, Leuven, Belgium; Winette T. van der Graaf, MD, PhD, Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Noah Federman, MD, Departments of Pediatrics and Orthopedics, UCLA Jonsson Comprehensive Cancer Center, UCLA David Geffen School of Medicine, Los Angeles, CA; Nam Q. Bui, MD, Division of Oncology, Department of Medicine, Stanford University, Stanford, CA; Gina D'Amato, MD, Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL; Richard F. Riedel, MD, Duke Cancer Institute, Duke University Medical Center, Durham, NC; Steven Attia, DO, Department of Hematology and Oncology, Mayo Clinic, Jacksonville, FL; Sant Chawla, MD, Sarcoma Oncology Center, Santa Monica, CA; Allison Lim, PharmD, Brad Tumminello, PharmD, and Ana B. Oton, MD, SpringWorks Therapeutics, Inc, a healthcare company of Merck KGaA, Darmstadt, Germany; Yucheng Chu, MS, Sumptuous Data Sciences, Monmouth Junction, NJ; Shengfan Zhou, MS, SpringWorks Therapeutics, Inc, a healthcare company of Merck KGaA, Darmstadt, Germany; and Mrinal Gounder, MD, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY.ORCID 0000-0001-8468-0119
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.